Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1530/eje.0.1400373
European Journal of Endocrinology, Vol 140, Issue 5, 373-375
Copyright © 1999 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krassas, G.
Right arrow Articles by Kahaly, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krassas, G.
Right arrow Articles by Kahaly, G.
Articles

The role of octreoscan in thyroid eye disease

GE Krassas and GJ Kahaly

Department of Endocrinology and Metabolism, Panagia Hospital, Thessaloniki, Greece.

Until recently there was no imaging technique available which could demonstrate pathological changes in orbital tissues and could be regarded as a reliable measure of inflammation in thyroid eye disease (TED). Pentetreotide (a synthetic derivative of somatostatin) labelled with 111In has been used to localize tumours which possess surface or membrane receptors for somatostatin in vivo using a gamma camera (1). This technique visualizes somatostatin receptors in endocrine-related tumours in vivo and predicts the inhibitory effect of the somatostatin analogue octreotide on hormone secretion by the tumours (1). By applying 111In-DTPA-d-Phe octreotide scintigraphy (octreoscan), accumulation of the radionuclide was also detected in both the thyroid and orbit of patients with Graves' disease (2-4). If peak activity in the orbit 5h after injection of radiolabelled octreotide is set at 100%, a decrease to 40+/-4% is found at 24h, significantly different from the decrease in blood pool radioactivity, which is 15+/-4% at 24h. Accumulation of the radionuclide is most probably due to the presence in the orbital tissue of activated lymphocytes bearing somatostatin receptors (5). Alternative explanations are binding to receptors on other cell types (e.g. myoblasts, fibroblasts or endothelial cells) or local blood pooling due to venous stasis by the autoimmune orbital inflammation.


This article has been cited by other articles:


Home page
 J EndocrinolHome page
R. Guillemin
Hypothalamic hormones a.k.a. hypothalamic releasing factors
J. Endocrinol., January 1, 2005; 184(1): 11 - 28.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. E. Krassas, N. Pontikides, T. Kaltsas, A. Dumas, J. Frystyk, J. W. Chen, and A. Flyvbjerg
Free and Total Insulin-Like Growth Factor (IGF)-I, -II, and IGF Binding Protein-1, -2, and -3 Serum Levels in Patients with Active Thyroid Eye Disease
J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 132 - 135.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. Pasquali, A. Notaro, G. Bonavolonta', P. Vassallo, A. Bellastella, and A. A. Sinisi
Somatostatin Receptor Genes Are Expressed in Lymphocytes from Retroorbital Tissues in Graves' Disease
J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 5125 - 5129.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. P. Weetman
Graves' Disease
N. Engl. J. Med., October 26, 2000; 343(17): 1236 - 1248.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 European Society of Endocrinology.